Pharmacological Correction of Neurological Disorders in Case of Multiple Sclerosis


multiple sclerosis

How to Cite

Nefedov, A. A., & Mamchur, V. I. (2015). Pharmacological Correction of Neurological Disorders in Case of Multiple Sclerosis. Galician Medical Journal, 22(4), 154-158. Retrieved from


The article analyzes the possibility of drug correction of common neurological disorders (pain, anxiety, depression, insomnia) using antidepressants under the conditions of experimental equivalent of multiple sclerosis on the background of basic drug therapy with methylprednisolone.

Assessment of antidepressants antinociceptive potential identified “a range of activity” of the mentioned medicines (analgesic activity of classical amitriptyline antidepressant was accepted as conventional unit): paroxetine (0.9 c.u.), amitriptyline (1 c.u.), fluoxetine (1.11 c.u.) and trittico (1.16 c.u.).

Comparative analysis of the duration of animals’ fading in the water at the forced swimming (Porsolt forced swimming test) found that the ability to weaken the level of anxiety and concern was the most significant for trittico and paroxetine groups. Immobilization time was 1.7 (p£0.05) and 1.6 (p£0.05), respectively, which was shorter than the corresponding figures of the active control group. The effect of antidepressants on latency, sleep duration when administered on a background of basic drug therapy with methylprednisolone was characterized by the following indicators: trittico (-66.5% and + 133.45%)³fluoxetine (-60.5% and + 117.79%)³paroxetine (-61.8% and + 93.59%)³amitriptyline (-52.75% and + 81.85%).

Thus, trittico and paroxetine were reasonable to administer under the experimental equivalent of multiple sclerosis taking into account the basic hormonal therapy as a means of drug correction of pain, anxiety, depression and sleep disorders.



Voloshyna NP, Ehorkyna OV. The problem of multiple sclerosis in Ukraine. Pharmacological treatment of MS study. Naukovyy sympozium z mizhnarodnoyu uchastyu «Medychni ta sotsialni aspekty reabilitatsii v nevrolohii, psykhiatrii i narkolohii». Kyiv. 24–25 November, 2011; 23-27.

Husev EY, Zavalyshyn YA, Boyko AN. Multiple sclerosis. Moscow. Real Taym. 2011; 520.

Stefanov OV. Preclinical studies of drugs (guidelines). Kyiv. Publishing house “Avitsena”. 2001; 450.

Korsunska O.I., Nef'odov OO. Immunotropic drugs in the general practitioner (ATC directory). Dnipropetrovsk. “Litohraf”. 2015; 203.

Lapach SN, Chubenko AV, Babych PN. Statistical methods in biomedical research using EXCEL. Kyiv. “Moryon”. 2001; 408.

Kozhemiakin YuM, Khromov OS, Filonenko MA. Scientific and practical advice on keeping laboratory animals and work with them. Kyiv. 2002; 155.

Nef'odov OO, Mamchur VJ, Kharchenko YuV. Feedback on modeling and experimental allergic encephalomyelitis. Visnyk problem biolohii i medytsyny. 2014; 2 (114): 205-8.

Nef'odov OO, Mamchur VY, Korsunska OI. The role of immunotherapy in patients with multiple sclerosis in the practice of family doctor. Visnyk problem biolohiyi i medytsyny. 2014; 4. 1 (113): 25-30.

Karkyshchenko VN, Kapanadze HV, Dengina SE. Development of methodology for assessing the physical endurance of small laboratory animals to study adaptogenic activity of certain drugs. Biomeditsina. 2011; 1: 72-74.

Brune K, Lanz K. Mode of action peripherical analgesic. Arzneimittel – Forsch. 1984; 34. 9a: 1060–65.

Magliozzi R, Howell O, Vora A. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007; 130: 1089–1104.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.